Search - tctmd.com

Displaying 21 - 40 of 59

Sort: Relevancy | Date

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

Todd Neale

March 19, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

Presentation ACC 2017

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

Presenter: Justin E Davies

March 19, 2017

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

Presentation ACC 2017

The RAD-MATRIX Study

Presenter: Alessandro Sciahbasi

March 19, 2017

News Conference News ACC 2017

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

Todd Neale

March 18, 2017

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Two

Shelley Wood

March 18, 2017

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

L.A. McKeown

March 18, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

Presentation ACC 2017

ORION-1: Primary Efficacy & Safety Outcomes

Presenter: Kausik K. Ray

March 17, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

Advertisement

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Live From Washington: ACC 2017, Day Three

The RAD-MATRIX Study

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Live From Washington: ACC 2017, Day Two

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

ORION-1: Primary Efficacy & Safety Outcomes

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content